The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Barriers to accrual and enrollment in brain tumor trials.
 
Eudocia Quant Lee
Honoraria - Medlink; UpToDate
Consulting or Advisory Role - Lilly
 
Ugonma Nnenna Chukwueke
No Relationships to Disclose
 
Shawn L. Hervey-Jumper
No Relationships to Disclose
 
John Frederick De Groot
Employment - Helsinn Therapeutics (I); ZIOPHARM Oncology (I)
Leadership - ZIOPHARM Oncology (I)
Stock and Other Ownership Interests - Gilead Sciences; ZIOPHARM Oncology (I)
Consulting or Advisory Role - Abbvie; Agios; AstraZeneca; Blue Earth Diagnostics; Boston Biomedical; CarThera; Deciphera; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; GenomiCare; GW Pharmaceuticals; Insys Therapeutics; Kadmon; Kairos Ventures; KIYATEC; Merck; Mundipharma Research; Novogen; Vascular Biogenics
Research Funding - Deciphera; EMD Serono; Lilly; Mundipharma; Novartis; Sanofi
Patents, Royalties, Other Intellectual Property - AstraZeneca - Research Support; Deciphera Pharmaceuticals - Research Support; Eli Lilly - Research Support; EMD-Serono - Research Support; Novartis - Research Support; Sanofi-Aventis - Research Support
Travel, Accommodations, Expenses - Blue Earth Diagnostics
 
Jose Pablo Leone
Research Funding - Kazia Therapeutics (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst)
 
Terri S. Armstrong
Consulting or Advisory Role - Abbvie; ImmunoCellular Therapeutics; Tocagen
Research Funding - Merck/Schering Plough
 
Susan Marina Chang
Research Funding - Agios (Inst); Novartis (Inst)
 
David Arons
No Relationships to Disclose
 
Kathy Rose Oliver
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); GlaxoSmithKline
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
 
Evanthia Galanis
Consulting or Advisory Role - Abbvie (Inst); Genentech/Roche (Inst); Oncorus
Research Funding - Genentech/Roche (Inst); Merck (Inst)
 
Bret Edward Buckley Friday
No Relationships to Disclose
 
Nancy U. Lin
Consulting or Advisory Role - Daiichi Sankyo; Genentech/Roche; Novartis; Puma Biotechnology; Seagen
Research Funding - Genentech; Novartis; Pfizer; Seagen
Patents, Royalties, Other Intellectual Property - Royalties for chapter in Up-to-Date regarding management of breast cancer brain metastases
 
Minesh P. Mehta
Leadership - Oncoceutics
Consulting or Advisory Role - Abbvie; AstraZeneca; Blue Earth Diagnostics; Celgene; Tocagen; Varian Medical Systems
Research Funding - Novocure (Inst)
Patents, Royalties, Other Intellectual Property - WARF patent 14/934,27, TOPICAL VASOCONSTRITOR PREPARATIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY
 
Marta Penas-Prado
Consulting or Advisory Role - AGIOS; Lilly
Research Funding - Abbvie (Inst); Agios (Inst); AROG (Inst); DelMar Pharmaceuticals (Inst); DNAtrix (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Novartis (Inst); Orbus Therapeutics (Inst)
 
Michael A. Vogelbaum
Stock and Other Ownership Interests - Infusion Therapeutics
Honoraria - Medicenna
Research Funding - DNAtrix (Inst); Infusion Therapeutics (Inst); Medicenna (Inst); Tocagen (Inst)
Patents, Royalties, Other Intellectual Property - Patents for drug delivery devices for the brain
Travel, Accommodations, Expenses - Infusion Therapeutics
 
Solmaz Sahebjam
Honoraria - Bristol-Myers Squibb; Merck Serono
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono
Research Funding - Bristol-Myers Squibb (Inst); Cortice Bioscience (Inst); Merck Serono (Inst)
 
Martin J. Van Den Bent
Consulting or Advisory Role - Abbvie; Agios; Bristol-Myers Squibb; Celgene; Celldex; Daiichi Sankyo; MSD
Research Funding - Abbvie (Inst)
 
Michael Weller
Honoraria - Merck Serono; MSD; Novocure; Roche
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Merck Serono; Orbus Therapeutics; Pfizer; Teva; Tocagen
Research Funding - Bayer (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novocure (Inst); OGD2 Pharma (Inst); Piqur (Inst); Roche (Inst); Tragara (Inst)
 
David A. Reardon
Honoraria - Abbvie; Advantagene; Agenus; Bristol-Myers Squibb; Bristol-Myers Squibb; Cavion; Celldex; EMD Serono; Genentech/Roche; Inovio Pharmaceuticals; Juno Therapeutics; Merck; Merck; Merck KGaA; Midatech Pharma; Momenta Pharmaceuticals; Monteris Medical; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline Therapeutics; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; Agenus; Bristol-Myers Squibb; Cavion; Celldex; EMD Serono; Genentech/Roche; Inovio Pharmaceuticals; Juno Therapeutics; Merck; Merck; Merck KGaA; Midatech Pharma; Momenta Pharmaceuticals; Monteris Medical; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline Therapeutics; Taiho Pharmaceutical
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Celldex (Inst); EMD Serono (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); Midatech Pharma (Inst); Omniox; Tragara (Inst)
 
Patrick Y. Wen
Consulting or Advisory Role - AbbVie; Agios; AstraZeneca; Deciphera; Genentech/Roche; GW Pharmaceuticals; Immunomic Therapeutics; KIYATEC; Lilly; Puma Biotechnology; Taiho Pharmaceutical; Tocagen; Vascular Biogenics; VBI Vaccines; ZIOPHARM Oncology
Speakers' Bureau - Merck; Prime Oncology
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Beigene (Inst); Genentech/Roche (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Vascular Biogenics (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)